Repligen Corporation Stock 12‑Month Price Target Raised to $180.33, Implies 38% Upside
Analyst estimates for Repligen (RGEN) show the average 12-month price target increased from $176.28 to $180.33, based on 18 analysts. Targets range from $145 to $220. Using the Jul. 27 close, the target implies about 38% upside. The consensus rating remains “Buy” with 19 Buys, 3 Holds, and 0 Sells.
How this was made
The 30-second read
Why it matters
A higher consensus target and implied upside may attract incremental dip-buying or momentum, but it is not the same as fresh guidance, earnings, or a contract/regulatory event.
Market read
Useful for sentiment and positioning around analyst consensus, but lacks a new fundamental trigger.
What to watch
The article does not state what drove the PT increase (earnings, guidance, contract wins), so traders should verify whether any underlying new information exists elsewhere.
Background
The piece summarizes FactSet-derived consensus analyst targets and rating distribution for Repligen.
Ticker impact
Repligen (RGEN) average 12-month analyst price target rose from $176.28 to $180.33, implying about 38% upside versus the Jul. 27 close.
Likely modest, sentiment-driven support; follow-through depends on whether the PT change reflects new earnings or guidance (not provided here).
The article reports only consensus price-target movement and rating mix, with no new company-specific operational or financial datapoint.
Market effects
Limited sector read-through because the update is purely analyst-target related with no disclosed sector catalyst.
None indicated; this is a single-name analyst consensus update.
None indicated; no cross-border deal, regulation, or macro driver mentioned.
Counterpoint
Price-target revisions can lag or merely reflect existing expectations; without new fundamentals, the market may discount the change quickly.
Key entities
- companyRepligen Corporation
Consensus analyst price target raised to $180.33, implying ~38% upside from the Jul. 27 close; rating remains Buy.
